IMARC Group has recently released a new research study “insomnia market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What are the growth prospects of the insomnia Industry?

The global insomnia Market size reached US$ 4.87 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of  US$ 5.93 Billion  by 2027, exhibiting a growth rate (CAGR) of 3.22% during 2022-2027.

Request For Sample Report: https://www.imarcgroup.com/insomnia-market/requestsample

What is a insomnia market ?

Insomnia refers to a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, etc., and excessive consumption of nicotine, caffeine, alcohol, etc.

Insomnia can also be associated with mental health disorders, including post-traumatic stress and the use of drugs, such as antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergies, cold, etc. Its treatment options, including cognitive-behavioral therapy (CBT), over-the-counter (OTC) sleep aids, and prescription medications, such as Eszopiclone and Ramelteon, are currently available across various countries.

Covid-19 Impact:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report. 

What are the major market drivers in the Insomnia Market: 

The increasing prevalence of social isolation, work challenges, and family obligations, owing to the sudden outbreak of the COVID-19 pandemic, is among the key factors stimulating the insomnia market. Apart from this, the rising incidences of stressful events that impact the sleep patterns of individuals are also propelling the market growth.

Besides this, the inflating cases of medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson’s disease, and Alzheimer’s disease, are further fueling the global market.

Additionally, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is also driving the market growth. Moreover, the elevating investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are expected to positively influence the insomnia market over the forecasted period. 

Click here to view detailed information with table of content: https://www.imarcgroup.com/insomnia-market

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Therapy Type:

Non-Pharmacological Therapy

o   Hypnotherapy

o   Cognitive Behavioral Therapy

o   Medical Devices

o   Others

Pharmacological Therapy

o   Prescription Sleep Aids

o   Over-The-Counter Sleep Aids 

Breakup by Drug Class:

o   Antidepressants

o   Melatonin Antagonist

o   Benzodiazepines

o   Nonbenzodiazepines

o   Orexin Antagonist

o   Others 

Breakup by Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Drug Stores

o   Online Pharmacies 

By Geography:

•             North America (United States, Canada)

•             Europe (Germany, France, United Kingdom, Italy, Spain, Others)

•             Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)

•             Latin America (Brazil, Mexico, Others)

•             Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

List of Major Key Players:

The major players in the market are

Astellas Pharma Inc.

 Aurobindo Pharma Limited

 Biocodex, Eisai Co. Ltd.

 Mallinckrodt Pharmaceuticals

 Merck & Co. Inc.

Neurim Pharmaceuticals Inc.

Pfizer Inc., Sanofi S.A.

Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.),

Takeda Pharmaceutical Company Limited

and Vanda Pharmaceuticals Inc.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800